Aducanumab (Aduhelm), a new drug designed to treat Alzheimer's disease was approved by the FDA on June 7, 2021. RGA's Dr. Dave Rengachary discusses what this means for insurance, as well as the controversies around it.
Munich Re assessed the Milliman Rx Risk Score, a predictive modeling tool developed and owned by Milliman that assesses mortality risk using an individual’s prescription drug information. Insurers considering prescription- drug-based scores should begin with a retrospective validation study on their own experience data.
Slides from this presentation, given at the 2018 ACSW Spring Meeting, have been posted at the Actuaries’ Club of the Southwest website.
Slides from the 2018 Wisconsin Association of Health and Life Underwriters have been posted at the WAHLU website.
Presentations include:
Dose and duration of therapy are associated with mortality for new antipsychotic users, according to a study published online May 10 in the Journal of the American Geriatrics Society.
 |
 |
 |
 |
 |
 |